JERSEY CITY, NJ, March 23, 2022 / PRNewswire / – InsightAce Analytic Pvt. Ltd. announces the release of a market rating report on the ” “Global Biosimilar Monoclonal Antibody Market by Product (infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products), Indication (Oncology, Inflammatory & Autoimmune Diseases, Inflammatory Diseases, Clinical Test / Pipeline Analysis, Future Trends, Industrial Competition Analysis, Revenue and Forecast by 2030.
According to the latest research, the global biosimilar monoclonal antibody market is estimated US $ 4.98 Billion in 2021, and it is expected to reach US $ 36.85 Billion by 2030, with a CAGR of 25% during the forecast period of 2022-2030.
Request for Sample Pages:
Biosimilars are biotherapeutic products. They are equivalent in terms of quality, efficiency and safety to an innovative reference drug. The AB biosimilars are complex biological macromolecules with various post-translation modifications. These biosimilars are used extensively to treat many chronic, inflammatory and autoimmune diseases. Some government agencies regulate biosimilars in different countries, such as the FDA in the US and the European Medicines Agency (EMEA) in Europe.
Global biosimilar monoclonal antibody market growth can be attributed to various factors, such as increasing demand for cost-effective biosimilars, increasing production of advanced monoclonal antibodies, growing geriatric population, high prevalence of chronic diseases such as cancer Kidney failure, rheumatoid arthritis, psoriasis, diabetes, and others. In addition, the increase in the patent flow of many mAbs is expected to strengthen the market growth opportunities over the forecast years. Increased patent claims by top-selling antibodies have encouraged pharmaceutical companies to develop biosimilars for mAbs, possibly accelerating the market during the forecast period.
However, the growth of the market is expected to be hampered by the complexities in the manufacture of biological drugs, the scarcity of clinical testing expertise, strict government policies for product approvals, and the lack of knowledge and understanding among manufacturers about biosimilar regulation and authorization.
The Asia Pacific The region is expected to gain significant growth over the forecast period (2020-2030) due to the increasing burden of chronic diseases, the growing need for cost-effective treatments, and the increasing government funding for the improvement of health care facilities.
Request for Sample Report: https://www.insightaceanalytic.com/report/global-biosimilar-monoclonal-antibodies-market/1218
Major market players operating in the biosimilar monoclonal antibody market include Pfizer (US), Novartis (Switzerland), Allergan (Ireland), Coherus BioSciences (US), Biocon (Bengaluru), Amgen (US), Boehringer Ingelheim (Germany), Celltrion (South Korea), BioXpress Therapeutics (Switzerland), Intas Pharmaceuticals Limited (Gujarat), Genor BioPharma Co.China), BIOCAD (Russia) among others.
Key developments in the market:
- In the July 2021, Abzena (UK), a global partner research organization for Biology and Bioconjugates, and BioXpress Therapeutics (Switzerland) collaborated to support biosimilar development for third-party customers. This partnership has created an integrated solution between two leading service providers in biosimilar development and GMP manufacturing.
- In the February 2020, Mylan (US) launches trastuzumab Biosimilar, Ogivri. Trastuzumab is a monoclonal antibody used to treat human epidermal growth factor receptor 2 (HER2) receptor-positive breast cancer, previously marketed by Genentech as Herceptin.
- In the June 2019, Amgen (US) and Allergan (Ireland) has announced FDA approval for KANJINTI ™ (trastuzumab-anns). It is approved for all indications of the reference product, Herceptin® (trastuzumab), which offers an additional treatment option for patients with three types of cancer.
March Segments
Global Biosimilar Monoclonal Antibody Market, by Product2020-2030 (Value US $ Mn)
- Infliximab
- Trastuzumab
- Rituximab
- Adalimumab
- Bevacizumab
- Cetuximab
- Ranibizumab
- Denosumab
- Eculizumab
- Other Pipeline Products
Global Biosimilar Monoclonal Antibody Market, by Indication2020-2030 (Value US $ Mn)
- Oncology
- Inflammatory and autoimmune diseases
- Chronic diseases
- Blood disorders
- Another indication
Global Biosimilar Monoclonal Antibody Market, by Region2020-2030 (Value US $ Mn)
- North America
- Europe
- Asia Pacific
- latin america
- The Middle East & Africa
North America Biosimilar Monoclonal Antibody Market, by Land2020-2030 (Value US $ Mn)
Europe Biosimilar Monoclonal Antibody Market, by Land2020-2030 (Value US $ Mn)
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific Biosimilar Monoclonal Antibody Market, by Land2020-2030 (Value US $ Mn)
- India
- China
- Japan
- South Korea
- Australia & New Zealand
Latin America Biosimilar Monoclonal Antibody Market, by Land2020-2030 (Value US $ Mn)
- Brazil
- Mexico
- Rest of latin america
The Middle East & Africa Biosimilar Monoclonal Antibody Market, by Land2020-2030 (Value US $ Mn)
- GCC countries
- South Africa
- Rest of The Middle East & Africa
Why should I get this report:
- To obtain a thorough clinical study / pipeline analysis of the prospects for the global biosimilar monoclonal antibody market
- To get a market overview and future trends of the biosimilar monoclonal antibody industry
- To analyze the biosimilar monoclonal antibody market challenges and challenges
- To get information about the biosimilar monoclonal antibody market size (value US $ Mn) forecast until 2030
- Major investments, mergers & acquisitions in the biosimilar monoclonal antibody market industry
For more information @ https://www.insightaceanalytic.com/report/global-biosimilar-monoclonal-antibodies-market/1218
Other related reports published by InsightAce Analytic:
Global Trastuzumab Biosimilar March
Global Adalimumab Biosimilar March
Global Infliximab Biosimilar March
Global Bevacizumab Biosimilar March
About us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help customers gain a competitive advantage by identifying unused markets, discovering new and competitive technologies, segmenting potential markets and repositioning products. Our expertise is to provide syndicated and personalized market intelligence reports with a detailed analysis with key market insights in a timely and cost effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Tel .: +1 718 593 4405
Email: [email protected]
Site Visited: www.insightaceanalytic.com
Follow us on LinkedIn @ bit.ly/2tBXsgS
Follow us on Facebook @ bit.ly/2H9jnDZ
SOURCE InsightAce Analytic Pvt. Ltd.
Add Comment